Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016337 | 1.00 | CHRNB4 (0.32) | CHRNB4CHRNA3PGR | |
| SCHEMBL12410568 | 0.82 | CA12 (0.32) | — | |
| SCHEMBL320467 | 0.82 | CA12 (0.38) | — | |
| SCHEMBL1203661 | 0.82 | SLC6A4 (0.31) | — | |
| SCHEMBL9395507 | 0.82 | SLC6A4 (0.31) | — | |
| SCHEMBL21239421 | 0.76 | CHRNB4 (0.32) | CHRNB4CHRNA3 | |
| SCHEMBL21161448 | 0.76 | CHRNB4 (0.32) | CHRNB4CHRNA3 | |
| SCHEMBL24269982 | 0.76 | — | — | |
| SCHEMBL15215911 | 0.76 | AR (0.32) | — | |
| SCHEMBL16955600 | 0.73 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805062-B | Imidazo [1,2-b ] pyridazines as Trk inhibitors | 博善人工智能生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070238878-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-10-11 | — | — | US | disclosed |
| US-20070238878-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-10-11 | — | — | US | disclosed |
| US-20070238878-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-10-11 | — | — | US | disclosed |
| CN-1332959-C | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2007-08-22 | — | — | CN | disclosed |
| EP-1807394-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | Neurosearch Sweden AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007042295-A1 | 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MDULATORS OF DOPAMINE? NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006040156-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NEUROSEARCH SWEDEN AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| CN-1649865-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2005-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | CHRNB4 3243/4885CHRNA3 3361/4885PGR 3543/4885 |
| US-20070238878-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | CAT, SQOR, CYP2B6 | CHRNB4 4143/4885CHRNA3 4386/4885PGR 2432/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | CHRNB4 2412/4885CHRNA3 2728/4885PGR 283/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | CHRNB4 3818/4885CHRNA3 3264/4885PGR 2430/4885 |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | TNK2, TNIK, TNK1 | CHRNB4 1591/4885CHRNA3 1443/4885PGR 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.